FDA Approves Rusfertide (Mimrylo) for Polycythemia Vera: A New Option for Erythrocytosis

What the approval changes

For a person living with polycythemia vera, the treatment history may be recorded in a notebook: the month blood was removed, the next hematocrit result, another procedure a few weeks later. The FDA’s August 2026 novel drug approval record identifies rusfertide for erythrocytosis in adults with the disease. That adds a drug aimed at excess red-cell production, which has often been managed with repeated phlebotomy, sometimes alongside hydroxyurea, interferon, ruxolitinib, or another cytoreductive approach.

Rusfertide is a hepcidin mimetic. It restricts the iron available for erythropoiesis, with the goal of controlling hematocrit without repeatedly removing blood. That is different from phlebotomy, which quickly removes circulating red cells and iron, and from conventional cytoreductive drugs, which suppress bone marrow production more broadly.

The practical change is more complicated than replacing a procedure with a drug. Clinicians must consider whether the burden recorded in that notebook, along with unstable hematocrit control or effects from repeated iron depletion, is enough to support systemic treatment, while also deciding whether rusfertide would address erythrocytosis alone or sit beside cytoreduction used for broader disease management and thrombotic risk.

FDA approval means the agency found a favorable benefit-risk balance for the labeled population. It does not show that rusfertide prevents thrombosis, delays progression to myelofibrosis or acute leukemia, or extends survival. Those questions need longer studies designed around those outcomes.

Evidence behind hematocrit control

The case for controlling hematocrit in polycythemia vera was established before rusfertide. In the randomized CYTO-PV study, 365 adults were assigned to a hematocrit target below 45% or a target of 45% to 50%. After a median follow-up of 31 months, cardiovascular death or major thrombosis had occurred in 2.7% of the lower-target group and 9.8% of the higher-target group. The hazard ratio for the higher target was 3.91, with a 95% confidence interval of 1.45 to 10.53 and a P value of 0.007.

That study supports keeping hematocrit below 45%. It did not test rusfertide, and it did not prove that every route to the target has the same effect on thrombosis.

A published phase 2 study enrolled 70 adults with polycythemia vera who needed frequent phlebotomy. During a 28-week open-label dose-finding period, the estimated mean number of phlebotomies dropped from 8.7 in the 28 weeks before enrollment to 0.6 during treatment. That is a striking difference on the page, but the comparison was not concurrently controlled, leaving it open to selection, expectancy, and changes over time.

The firmer efficacy test came in a 12-week, double-blind randomized withdrawal phase. Among participants who entered that phase, 60% of those continuing rusfertide met the prespecified response definition, compared with 17% of those switched to placebo; the reported P value was 0.002. Average maximum hematocrit was 44.5% with rusfertide and 50.0% with placebo.

Because participants had already received the drug before randomization, the withdrawal design gives useful evidence that continued treatment caused better short-term hematocrit and phlebotomy control among prior responders, though it tells us less about what happens across all patients starting therapy for the first time.

The phase 3 VERIFY study was designed to compare rusfertide with placebo in adults with phlebotomy-dependent polycythemia vera, including people on stable background therapy. The FDA decision reflects the agency’s review of the full application, not one publication. The final prescribing information defines the eligible population, administration schedule, warnings, and monitoring requirements.

Treatment selection after approval

Phlebotomy remains fast, familiar, and relatively inexpensive. It has an established role in maintaining hematocrit below 45%. The drawbacks become harder to dismiss when the notebook keeps filling: another visit, another blood draw, trouble finding venous access, a hematocrit that rises again, and progressive iron depletion after repeated procedures.

Rusfertide allows clinicians and patients to treat those burdens as part of the treatment decision rather than as background inconveniences that must always be accepted. Still, fewer phlebotomies do not mean that every other piece of care falls away.

Cytoreductive therapy answers a different question. Someone may need it because of age, a previous thrombosis, difficult blood-count control, symptoms, or other disease features even if rusfertide controls erythrocytosis. Another adult whose main difficulty is recurrent phlebotomy may not need broader marrow suppression merely because a systemic treatment for erythrocytosis is now available. The approval makes that distinction easier to see, though not necessarily easier to resolve.

Background treatment matters when reading the rusfertide evidence. Studies permitted stable cytoreductive therapy, so rusfertide should not be assumed to replace hydroxyurea, interferon, or ruxolitinib. In some patients, it may be added to reduce phlebotomy and control hematocrit while another treatment continues to address elevated white-cell or platelet counts, an enlarged spleen, or symptoms.

Safety and day-to-day feasibility will shape those decisions. Injection-site reactions were common in the phase 2 report, and the drug’s mechanism intentionally changes how iron is distributed. Monitoring is set out in the FDA-approved label, including safety warnings and laboratory recommendations.

The burden also changes form rather than vanishing. A patient may cross out phlebotomy entries in the notebook and still face ongoing medication administration, lab work, insurance authorization, and out-of-pocket costs. Access may determine what is realistic long before the clinical discussion feels finished.

Shared decisions have to reach beyond the number of procedures. Prior phlebotomy frequency, the stability of hematocrit below 45%, possible symptoms related to iron depletion, concurrent cytoreduction, thrombotic history, comfort with injections, and access to treatment can all matter. None establishes that rusfertide will improve an individual patient’s long-term outcome.

Important evidence gaps

The randomized phase 2 comparison lasted 12 weeks and used a withdrawal design that favored enrollment of people who had already remained on rusfertide through the earlier phase. Its response endpoint focused on hematocrit and phlebotomy, not thrombosis, disease progression, or survival. The manufacturer funded the study, which makes full reporting and independent confirmation important.

The findings may not travel evenly across the broader patient population. Trial participants had substantial phlebotomy requirements before enrollment and met study eligibility criteria, while people seen in ordinary practice may have infrequent procedures, unstable background treatment, or medical conditions that were uncommon in the trial.

Longer follow-up is needed to understand how durable the response is, what sustained changes in iron handling mean, whether uncommon adverse events emerge, and what happens after treatment stops. One unresolved question matters especially: whether reducing the procedures written in the notebook, while still controlling hematocrit, leads to fewer thrombotic events, better sustained quality of life, or stronger adherence. Current evidence supports hematocrit and phlebotomy control. It has not established disease modification.

Questions clinicians ask

Does rusfertide replace phlebotomy?

Not across the board. Rusfertide offers a systemic way to reduce phlebotomy requirements while maintaining hematocrit control, but phlebotomy remains an effective rapid intervention. Its place depends on the FDA label, the patient’s prior procedure burden, hematocrit stability, access, and ability to continue drug administration and monitoring.

Can cytoreductive therapy be stopped when rusfertide begins?

The evidence does not support stopping it automatically. Rusfertide primarily addresses erythrocytosis by restricting iron availability, while cytoreductive treatment may have been chosen for broader concerns involving thrombotic risk, elevated white-cell or platelet counts, an enlarged spleen, or symptoms. The reason that background treatment was started still matters.

Has rusfertide been shown to prevent thrombosis?

No definitive reduction in thrombosis has been demonstrated. Rusfertide improved short-term hematocrit and phlebotomy outcomes. The evidence linking a target below 45% with fewer cardiovascular deaths or major thrombotic events comes from a separate study of treatment intensity, not from a rusfertide outcomes trial.

Which patients are the clearest candidates?

The evidence applies most directly to adults with polycythemia vera who continue to need recurrent phlebotomy despite otherwise appropriate management. The labeled indication, background cytoreduction, procedure burden, iron-related concerns, tolerance for injections, safety monitoring, and access all enter the discussion. Evidence is less direct for people who rarely need phlebotomy or do not need it at all. Their notebook may have only one entry.

Questions people ask

Does rusfertide replace phlebotomy for polycythemia vera?

Rusfertide reduced phlebotomy needs while maintaining hematocrit control in studied adults. Phlebotomy remains a rapid, established option, and the treatment burden shifts toward injections, laboratory monitoring, access, and cost.

Can cytoreductive therapy be stopped after starting rusfertide?

The evidence did not support automatically stopping cytoreductive treatment. Rusfertide mainly addressed erythrocytosis, while hydroxyurea, interferon, ruxolitinib, or other treatments may still address broader blood-count, spleen, symptom, or thrombotic concerns.

Does rusfertide prevent blood clots in polycythemia vera?

Rusfertide improved short-term hematocrit and phlebotomy outcomes, but it has not definitively reduced thrombosis. The evidence connecting hematocrit below 45% with fewer major thrombotic events came from a separate treatment-intensity study, not a rusfertide outcomes trial.

References

1. Novel Drug Approvals for 2026 — US Food and Drug Administration, 2026 2. Rusfertide for Erythrocytosis in Polycythemia Vera — The New England Journal of Medicine, 2024 3. A Study of Rusfertide in Patients With Polycythemia Vera (VERIFY) — ClinicalTrials.gov, 2022 4. Cardiovascular Events and Intensity of Treatment in Polycythemia Vera — The New England Journal of Medicine, 2013